Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine.

BACKGROUND

Zoster vaccination is recommended for people with a history of herpes zoster (HZ), but the most effective timing of vaccine administration after zoster illness is unresolved. This prospective observational study compared the immunogenicity and safety of administering HZ vaccine at 6-12 months and 1-5 years after zoster illness.

MATERIALS AND METHODS

Blood samples were collected before the administration of live zoster vaccine and 6 weeks after vaccination. Varicella-zoster virus (VZV) IgG concentrations and T-cell responses were assessed by glycoprotein enzyme-linked immunosorbent assay and interferon-γ enzyme-linked immunospot assay (ELISPOT), respectively.

RESULTS

The baseline geometric mean value (GMV) of VZV IgG was higher in the 6-12 months group than in the 1-5 years group (245.5 IU/mL vs. 125.9 IU/mL; = 0.021). However, the GMV increased significantly in both groups ( = 0.002 in the 6-12 months group; <0.001 in the 1-5 years group). The results of the ELISPOT assay were not significant for differences of the GMV between baseline and 6-week post-vaccination groups, while the GMV increased significantly in both groups ( = 0.001 in the 6-12 months group; <0.001 in the 1-5 years group).

CONCLUSION

The immunogenicity of zoster vaccine may be similar whether administered 6-12 months, or >1 year after zoster illness.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT02704572.